Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Resistant Cancer”

3,770 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 3,770 results

Testing effectiveness (Phase 2)Study completedNCT00428896
What this trial is testing

A Feasibility Study With Iressa in Resistant Cytokeratin-Positive Tumor Cells Circulating in the Blood of Women With Breast Cancer

Who this might be right for
Breast Cancer
University Hospital of Crete 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 23
Early research (Phase 1)Study completedNCT05708573
What this trial is testing

Potential Drug Interaction Between ALXN2040 and Rosuvastatin

Who this might be right for
Healthy Participants
Alexion Pharmaceuticals, Inc. 20
Testing effectiveness (Phase 2)Ended earlyNCT04375527
What this trial is testing

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Locally Advanced Cutaneous Melanoma+8 more
Jonsson Comprehensive Cancer Center 3
Early research (Phase 1)Ended earlyNCT00058773
What this trial is testing

Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease

Who this might be right for
Hodgkin DiseaseNon-Hodgkins Lymphoma
Baylor College of Medicine 5
Very early researchUnknownNCT02691169
What this trial is testing

Integrated 18F-labelled PSMA Project

Who this might be right for
Prostate Cancer
St. Joseph's Healthcare Hamilton 10
Testing effectiveness (Phase 2)Ended earlyNCT01093183
What this trial is testing

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer
University of Nebraska 25
Testing effectiveness (Phase 2)UnknownNCT04247256
What this trial is testing

Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI

Who this might be right for
Metastatic Colorectal Cancer
Scandion Oncology A/S 35
Not applicableEnded earlyNCT04370522
What this trial is testing

Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Spanish Breast Cancer Research Group 32
Not applicableLooking for participantsNCT06600802
What this trial is testing

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Who this might be right for
Castration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)
Centre Jean Perrin 120
Not applicableStudy completedNCT03223727
What this trial is testing

Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223

Who this might be right for
Prostate Cancer MetastaticBone Metastases
The Netherlands Cancer Institute 100
Early research (Phase 1)Looking for participantsNCT07316686
What this trial is testing

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

Who this might be right for
Prostate Cancer (Adenocarcinoma)
Instituto do Cancer do Estado de São Paulo 18
Not applicableNot Yet RecruitingNCT06694129
What this trial is testing

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

Who this might be right for
Non-Small Cell Lung CancerROS1 Gene RearrangementResistance+1 more
National Cancer Center, China 40
Early research (Phase 1)Study completedNCT03629756
What this trial is testing

Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Who this might be right for
Non-small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckBreast Cancer+9 more
Arcus Biosciences, Inc. 48
Not applicableUnknownNCT01989039
What this trial is testing

IR, Inflammatory and Cardiovascular Markers in PCOS Among Obese and Non-obese Women

Who this might be right for
Polycystic Ovary Syndrome,Insulin Resistance,
Taipei Medical University WanFang Hospital 800
Not applicableWithdrawnNCT01882972
What this trial is testing

Strength for Health

Who this might be right for
Colon Cancer
Loyola University
Large-scale testing (Phase 3)Ended earlyNCT02641639
What this trial is testing

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Who this might be right for
Platinum Resistant Ovarian Cancer
Mateon Therapeutics 70
Not applicableUnknownNCT06450145
What this trial is testing

Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL

Who this might be right for
Tumour
Zhejiang Provincial People's Hospital 15
Early research (Phase 1)Looking for participantsNCT06062745
What this trial is testing

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Who this might be right for
Advanced Prostate CancerMetastatic Prostate CancerMetastatic Prostate Neuroendocrine Carcinoma
Brigham and Women's Hospital 30
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Next Page